A chronological record of peer-reviewed Melanotan II research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Peptide research timelines are often misrepresented online. Claims about "how quickly Melanotan IIworks" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.
Primary mechanism studied: Non-Selective Melanocortin Agonism. Primary indications investigated: Skin tanning, Erectile dysfunction (research), Sun protection (research).
Analysis of 17 seized and commercial melanotan II preparations, documenting purity, contamination, and consistency issues in illicit products.
Small pilot series reporting that 4 of 6 men with erectile dysfunction using melanotan II for skin tanning experienced improved erectile function.
Comprehensive review of safety concerns regarding melanotan II, melanoma risk, and nevi development based on available human and preclinical data.
Preliminary studies examining melanotan II effects in depigmented skin conditions, including vitiligo and scleroderma-associated hypopigmentation.
Study examining whether melanotan II-induced pigmentation provides photoprotective effects in rodent skin against UV-induced DNA damage.
Review of melanotan II showing both tanning and sexual function effects via melanocortin receptor activation.
Preclinical studies establishing melanotan II effects on erectile function and libido in male and female rats via melanocortin pathways.
Study of melanotan II effects on cutaneous vasodilation, sweating, and thermoregulatory responses during thermal stress.
Study of how MC1R genetic variants affect receptor function and responsiveness to melanotan II stimulation in transfected cell lines.
Study of melanotan II effects on blood pressure, heart rate, and cardiac hemodynamics in normotensive and hypertensive rats.
Cell culture study examining melanotan II effects on melanin synthesis and melanoma cell proliferation in primary human melanocytes.
Comprehensive review of central melanocortin system anatomy, function, and effects of melanocortin agonism on appetite, energy expenditure, and sexual behavior.
Mechanistic studies showing melanotan II suppresses feeding via MC4R activation and inhibition of NPY/AgRP neurons in the hypothalamus.
Comprehensive review of melanin synthesis pathways and regulation by melanocortin signaling, including feedback mechanisms in melanocytes.
Chemical stability and receptor binding studies of melanotan II and analogs under various conditions, informing formulation strategies.
Early human trial showing melanotan II increased pigmentation and suppressed hunger ratings in 18 fair-skinned subjects during 10-day treatment.
Mechanistic study establishing that non-selective melanocortin agonism (like melanotan II) suppresses feeding through MC4R but has off-target MC1R effects.
The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for Melanotan II is L3 (Emerging Clinical Evidence): pilot human studies or limited clinical trials available. Treat each study as one data point, not a conclusion.
PeptideMark indexes 59 studies on Melanotan II: 6 human studies, 35 animal studies, 10 in-vitro, and 8 reviews. The current evidence level is L3 — emerging clinical evidence.
The earliest indexed peer-reviewed study on Melanotan II in the PeptideMark library was published in 1997 (Science). Research activity has continued through 2014.
Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.
Published research activity on Melanotan II has slowed in recent years based on indexed studies. Ongoing investigator-initiated trials may exist that are not yet indexed.
Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.